Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Retirement

 In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 10th November, 2022 has inter-alia, considered and approved the following:- Mr. Jayshankar Menon (ICSI Membership No.11067) will retire as the Company Secretary and Compliance Officer of the Company with effect from the closure of business hours of 30th November, 2022.
10-11-2022
Bigul

Q2FY23 Quarterly Result Announced for Indoco Remedies Ltd.

 Pharmaceuticals company Indoco Remedies announced Q2FY23 results: Q2FY23: During the Second quarter of FY23, revenues of Indoco Remedies grew by 8.6 % at Rs 404.6 crore, as against Rs 372.6 crore, the same quarter last year EBIDTA to net sales for the quarter is 21.7 % at Rs 87.8 crore, compared to 23.2 % at Rs 86.3 crore, the same quarter last year For the quarter, the Profit After Tax to net sales is 12.3 % at Rs 49.6 crore, compared to 11.2 % at Rs 41.6 crore, the same quarter last year H1FY23: For the first half of FY23, the revenues grew by 6.1 % at Rs 799.5 crore, as against Rs 753.8 crore, the same period last year EBIDTA to net sales for the period is 19.9 % at Rs 159.1 crore, compared to 23.0 % at Rs 173.1 crore, the same period last year For the period, the Profit After Tax to net sales is 11.0 % at Rs 88.1 crore, compared to 10.8 % at Rs 81.2 crore, the same period last year Commenting on the second quarter FY 2022-23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “An excellent performance driven by international formulation sales and ably supported by domestic business has helped us deliver improved margins this quarter”. Result PDF
10-11-2022
Bigul

INDOCO REMEDIES LTD. - 532612 - Financial Results For The Quarter And Half Year Ended 30/09/2022

 The Board of Directors at their meeting held today, have approved and taken on record the Standalone & Consolidated Unaudited financial results of the Company for the second quarter/half year ended 30.09.2022. Enclosed please find copies of the following: a) Standalone & Consolidated unaudited results as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 b) Limited Review Certificate issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants. c) Press Release.
10-11-2022
Bigul

INDOCO REMEDIES LTD. - 532612 - Board Meeting Outcome for Outcome Of Board Meeting Dated 10Th November, 2022

 The Board of Directors at their meeting held today, have approved and taken on record the Standalone & Consolidated Unaudited financial results of the Company for the second quarter/half year ended 30.09.2022. Enclosed please find copies of the following: a) Standalone & Consolidated unaudited results as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 b) Limited Review Certificate issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants. c) Press Release. The meeting commenced at 10.45 am and concluded at 11.30 am.
10-11-2022
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 REVISED SCHEDULE OF CON CALL MEETING
08-11-2022
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 SCHEDULE OF CON CALL MEETING
07-11-2022
Bigul

INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for Intimation Of Board Meeting - Unaudited Financial Results For The Quarter & Half Year Ended September 30, 2022

 INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 ,inter alia, to consider and approve Intimation of Board Meeting - Unaudited Financial Results for the quarter & half year ended September 30, 2022
20-10-2022
Bigul

INDOCO REMEDIES LTD. - 532612 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 REGULATION 74(5) OF SEBI (DP) REGULATIONS,2018
13-10-2022
Bigul

INDOCO REMEDIES LTD. - 532612 - Statement Of Investor Complaints For The Quarter Ended September 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JAYSHANKAR MENONDesignation :- Company Secretary and Compliance Officer
11-10-2022
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Intimation of Schedule of Analyst / Institutional Investors Meet
06-10-2022
Next Page
Close

Let's Open Free Demat Account